Legend Biotech Corporation

NasdaqGS:LEGN Stock Report

Market Cap: US$9.2b

Legend Biotech Future Growth

Future criteria checks 5/6

Legend Biotech is forecast to grow earnings and revenue by 63.6% and 35.1% per annum respectively. EPS is expected to grow by 48.7% per annum. Return on equity is forecast to be 19.1% in 3 years.

Key information

63.6%

Earnings growth rate

48.7%

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth rate35.1%
Future return on equity19.1%
Analyst coverage

Good

Last updated10 Oct 2024

Recent future growth updates

Recent updates

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Sep 18

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Aug 01
Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Jul 30

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Jul 05
Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13
Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Mar 15

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Mar 06
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Legend Biotech: Solid Traction With Carvykti Rollout

Jan 29

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Jan 16
Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Nov 09
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Apr 12
Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Dec 14
An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Sep 27

Legend Biotech stock slides on proposed ADS offering

Jul 25

Legend Biotech ends Phase 1 trial for lymphoma candidate

Jul 07

News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Jun 05
News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

May 14
Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Mar 22
Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Legend Biotech: Carvykti Approval Makes For A Buy Opportunity

Mar 04

Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Mar 03
Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Dec 30
Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Earnings and Revenue Growth Forecasts

NasdaqGS:LEGN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,57613718920715
12/31/20251,020-166-168-17419
12/31/2024588-273-437-13718
6/30/2024456-285-165-143N/A
3/31/2024343-466-264-239N/A
12/31/2023285-518-416-393N/A
9/30/2023233-509-371-347N/A
6/30/2023165-532-378-359N/A
3/31/2023112-517-276-262N/A
12/31/2022117-446-224-201N/A
9/30/2022106-416-237-221N/A
6/30/202296-457-221-194N/A
3/31/2022119-346-293-250N/A
12/31/202169-404-244-198N/A
9/30/202193-356-245-185N/A
6/30/202189-297-259-205N/A
3/31/202180-340-256-204N/A
12/31/202075-266-253-223N/A
9/30/202059-310-300-227N/A
6/30/202064-271-209-143N/A
3/31/202061-165-160-125N/A
1/1/202062-102-110-83N/A
12/31/201849-3287308N/A
12/31/2017249N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LEGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: LEGN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: LEGN is expected to become profitable in the next 3 years.

Revenue vs Market: LEGN's revenue (35.1% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: LEGN's revenue (35.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LEGN's Return on Equity is forecast to be low in 3 years time (19.1%).


Discover growth companies